Immunology contributes about 12 % to the overall exosome diagnostic therapeutics market, driven by the need for precise immune‑status monitoring in autoimmune disorders and transplant medicine. Immune‑cell‑derived exosomes carry surface markers (e.g., CD63, CD81) and cytokine‑related miRNAs that reflect activation states of T‑cells, B‑cells, and macrophages. By profiling these vesicles, clinicians can detect subclinical graft‑rejection, quantify disease activity in conditions such as rheumatoid arthritis or systemic lupus erythematosus, and adjust immunosuppressive regimens accordingly. The segment’s momentum is supported by advances in multiplexed exosome‑analysis platforms, regulatory acceptance of exosome‑based companion diagnostics, and increasing clinical trials that evaluate exosome‑mediated delivery of anti‑inflammatory agents. Moreover, the convergence of exosome diagnostics with emerging cellular therapies (e.g., CAR‑T) creates synergistic opportunities that expand the segment’s revenue potential. In sum, immunology’s role in the exosome diagnostic therapeutics segmentation reflects its capacity to enhance patient management through granular immune profiling and targeted therapeutic delivery.
